The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study

Table 3

The comparison between cases with improvement of spontaneous bowel movements and cases without it.

	With improved; bowel movements; ()	Without improved; bowel movement; ()	value
Gender, (%)
Male	33 (42.9)	11 (40.7)	0.85
Female	44 (57.1)	16 (59.3)
Age, (%)
≤74	43 (55.8)	12 (44.4)	0.31
≥75	34 (48.1)	15 (55.6)
Laxative combination, (%)	43 (44.8)	17 (63.0)	0.52
Irritant laxative combination, (%)	21 (27.3)	6 (22.2)	0.61
Elobixibat dose, (%)
5 mg	18 (23.4)	4 (14.8)	0.53
10 mg	51 (66.2)	21 (77.8)
15 mg	8 (10.4)	2 (7.4)
Underlying disease, (%)
Dyslipidemia	26 (33.8)	9 (33.3)	0.97
Diabetes	16 (20.8)	5 (18.5)	0.80
Hepatic disorder	3 (3.9)	2 (7.4)	0.46
Hypothyroidism	4 (5.2)	0 (0)	0.23
Parkinson’s disease	3 (3.9)	0 (0)	0.30
Concomitant medication, (%)
Antacids	31 (40.3)	11 (40.7)	0.97
Antidepressants	7 (9.1)	4 (14.8)	0.41
Calcium antagonists	8 (10.4)	2 (7.4)	0.65
Parkinson’s disease drugs	3 (3.9)	0 (0)	0.30
Ursodeoxycholic acid	2 (2.6)	0 (0)	0.40